Psyence Biomedical Ltd

World's First Nasdaq listed Nature-Derived Psilocybin Biopharma arrives on Wall Street. Thank you Nasdaq for welcoming Psyence Biomedical Ltd (NASDAQ:PBM) #FollowThePsyence

Shareholder update from Psyence Biomedical Ltd, one of the world's few vertically integrated biopharmas with a focus on psychedelic-based pharmaceutical therapeutics, and the first life science biotechnology company developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine to be listed on Nasdaq •Phase IIb clinical trial progressing as planned; patient screening has commenced •Independent valuation of PsyLabs values Psyence Biomed’s stake at approximately $2 million, doubling in value •Strengthened balance sheet, with substantially reduced debt, heading into 2025 "We anticipate that Psyence Biomed will enter 2025 with a substantially debt-free balance sheet, offering greater financial flexibility and stability. This improved financial position allows the Company to focus its resources on advancing its clinical programs, including the ongoing Phase IIb trial in Adjustment Disorder and the planned Phase II trial in Alcohol Use Disorder (AUD), while positioning itself for long-term growth and operational efficiency," says Psyence Biomedical Ltd CEO Dr. Neil Maresky who adds, "In closing, I believe the progress that we have made this year – clinical, financial and operational – position us well to achieve multiple value-creating milestones in 2025 and beyond. "

The pioneer in working to develop safe, responsible, FDA-approved nature-derived (non-synthetic) psilocybin pharmaceutical candidates, Psyence Biomedical Ltd stands alone as the only @nasdaq-listed biopharmaceutical company to develop a nature-derived psilocybin candidate to treat Adjustment Disorder in the context of Palliative Care. Thanks to the team at Psychedelic Invest - Insights and Analyses on Psychedelics for telling some of the story of what it takes to bring this much-needed medical breakthrough to the patients who need it most.

Report from Benzinga's Juan Agustín Spinelli shares happy landmark reached in Psyence Biomedical Ltd's trajectory as the first life science biotechnology company developing nature-derived (non-synthetic) psilocybin mushroom-based psychedelic medicine to be listed on the NASDAQ. https://lnkd.in/ephrFpVq

Look forward to seeing everyone at the Fluence winter convening.

Weekend reading on Psyence Biomedical Ltd from Psychedelic Invest - Insights and Analyses on Psychedelics

One of the world's few vertically integrated biopharmas with a focus on nature-derived psychedelic-based pharmaceutical therapeutics writes the next chapter. https://lnkd.in/eRRT2MZh

Psychedelic Invest - Insights and Analyses on Psychedelics news blast courtesy of Adam Tubero Mabel Nash Greenberg and the team.

Double-down: Psyence Biomedical Ltd hits another milestone in developing a safe and effective, regulatory approved approach to nature-derived psilocybin for Palliative Care patients, long in need of new therapeutic options. https://lnkd.in/e7pPPwCN

Psychedelic Palliative Medicine in this issue of the Mary Ann Liebert, Inc.'s peer-reviewed Journal of Psychedelic Medicine: "Systemic Review of the Effect of Psychedelic-Assisted Therapy on Attitudes Toward Death, Life, and Spirituality on Symptoms of Distress, Depression, and/or Anxiety in Patients with Life-Threatening Illness," authored by Paul Glue and Thivya Turner. Background: The underlying mechanism(s) of action of psychedelic-assisted therapy (PAT) to reduce distress, depression, and/or anxiety symptoms in life-threatening illness are poorly understood. It has been postulated that addressing death anxiety, and components of spiritual and existential distress, may be mediating factors. Method: This systematic review describes the current evidence base regarding the impact of PAT on attitudes toward life, death, and spirituality. MEDLINE, Embase, PsychINFO, and PubMed databases were systematically searched for original clinical research articles on PAT for distress, depression, and/or anxiety symptoms in life-threatening illness, with outcome measures related to attitudes toward life, death, and spirituality. The risk of bias was assessed using Joanna Briggs Institute critical appraisal checklists. A descriptive analysis was conducted. Results: A total of 14 articles met the inclusion criteria. Improvements in distress, depression, and/or anxiety symptoms were associated with reduced demoralization, reduced hopelessness, improvements in spirituality, greater death acceptance, a greater sense of optimism toward life, and a greater sense of meaningful existence. Mixed results were found in other attitudes toward life and death. Conclusions: This review identifies several mechanisms by which PAT may improve distress, depression, and/or anxiety symptoms in patients with life-threatening illness, via effects on a range of attitudes toward life, death, and spirituality.